

## **Invitation to presentation of Devyser's Q2 2025 Interim Report**

On Tuesday July 22 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q2 2025 report (which will have been published earlier on July 22 at 07:30 a.m. CET).

The presentation will be held in English.

If you wish to participate via webcast please use the link below.

<https://devyser-diagnostics.events.inderes.com/q2-report-2025>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. <https://events.inderes.com/devyser-diagnostics/q2-report-2025/dial-in>

Speakers: Interim CEO Fredrik Dahl, CFO Sabina Berlin and CCO Theis Kipling

**For more information, please contact:**

Fredrik Dahl, interim CEO

Email: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

Sabina Berlin, CFO

Email: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50



**PRESS RELEASE**  
14 July 2025 09:30:00 CEST

### **About Devyser**

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

Discover how we're shaping the future of lab diagnostics at [www.devyser.com](https://www.devyser.com).